These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 23428467)

  • 1. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.
    Leão M; Pereira C; Bisio A; Ciribilli Y; Paiva AM; Machado N; Palmeira A; Fernandes MX; Sousa E; Pinto M; Inga A; Saraiva L
    Biochem Pharmacol; 2013 May; 85(9):1234-45. PubMed ID: 23428467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthones as Potential p53-Activating Agents.
    Lemos A; Gomes AS; Loureiro JB; Brandão P; Palmeira A; Pinto MMM; Saraiva L; Sousa ME
    Molecules; 2019 May; 24(10):. PubMed ID: 31121972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
    Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
    Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
    Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
    Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
    Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
    Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.
    Wong JH; Alfatah M; Sin MF; Sim HM; Verma CS; Lane DP; Arumugam P
    BMC Biol; 2017 Nov; 15(1):108. PubMed ID: 29121928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
    Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
    FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
    Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
    J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
    Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J
    J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction.
    Li J; Zhang S; Gao L; Chen Y; Xie X
    J Biomol Screen; 2011 Apr; 16(4):450-6. PubMed ID: 21471462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into the in vitro antitumor mechanism of action of a new pyranoxanthone.
    Palmeira A; Paiva A; Sousa E; Seca H; Almeida GM; Lima RT; Fernandes MX; Pinto M; Vasconcelos MH
    Chem Biol Drug Des; 2010 Jul; 76(1):43-58. PubMed ID: 20456373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
    Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
    J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
    Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Zhang Y; Guo Z; Yao J; Dong G; Wang S; Liu Y; Chen H; Sheng C; Zhang W
    Eur J Med Chem; 2011 Nov; 46(11):5654-61. PubMed ID: 21996465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
    Hardcastle IR; Liu J; Valeur E; Watson A; Ahmed SU; Blackburn TJ; Bennaceur K; Clegg W; Drummond C; Endicott JA; Golding BT; Griffin RJ; Gruber J; Haggerty K; Harrington RW; Hutton C; Kemp S; Lu X; McDonnell JM; Newell DR; Noble ME; Payne SL; Revill CH; Riedinger C; Xu Q; Lunec J
    J Med Chem; 2011 Mar; 54(5):1233-43. PubMed ID: 21314128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
    Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
    Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
    Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
    Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.